JP2012502900A - 抗癌剤並びにそれに関する転移性悪性黒色腫及び他の癌についての使用 - Google Patents

抗癌剤並びにそれに関する転移性悪性黒色腫及び他の癌についての使用 Download PDF

Info

Publication number
JP2012502900A
JP2012502900A JP2011526634A JP2011526634A JP2012502900A JP 2012502900 A JP2012502900 A JP 2012502900A JP 2011526634 A JP2011526634 A JP 2011526634A JP 2011526634 A JP2011526634 A JP 2011526634A JP 2012502900 A JP2012502900 A JP 2012502900A
Authority
JP
Japan
Prior art keywords
compound
diazenyl
dimethylamino
formula
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502900A5 (https=
Inventor
ゴカラジュ，ガンガ，ラジュ
カシナ，スダカー
ゴカラジュ，ラマ，ラジュ
ゴラコチ，トリムーツル
サムパリ，ヴェンカテスワール
クリシャヌ，セングプタ
ビューパチラジュ，キラン
Original Assignee
カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド filed Critical カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド
Publication of JP2012502900A publication Critical patent/JP2012502900A/ja
Publication of JP2012502900A5 publication Critical patent/JP2012502900A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011526634A 2008-09-15 2009-09-14 抗癌剤並びにそれに関する転移性悪性黒色腫及び他の癌についての使用 Pending JP2012502900A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2230/CHE/08 2008-09-15
IN2230CH2008 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (2)

Publication Number Publication Date
JP2012502900A true JP2012502900A (ja) 2012-02-02
JP2012502900A5 JP2012502900A5 (https=) 2012-10-25

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526634A Pending JP2012502900A (ja) 2008-09-15 2009-09-14 抗癌剤並びにそれに関する転移性悪性黒色腫及び他の癌についての使用

Country Status (11)

Country Link
US (1) US8258119B2 (https=)
EP (1) EP2324006B1 (https=)
JP (1) JP2012502900A (https=)
KR (1) KR20110063537A (https=)
CN (1) CN102149703B (https=)
AU (1) AU2009290365B2 (https=)
BR (1) BRPI0913485A2 (https=)
CA (1) CA2736732A1 (https=)
IL (1) IL211366A0 (https=)
NZ (1) NZ591394A (https=)
WO (1) WO2010029577A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120006554A (ko) * 2009-04-27 2012-01-18 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도
NO2686520T3 (https=) 2011-06-06 2018-03-17
EP2717870B1 (en) * 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
US10221198B2 (en) 2014-06-27 2019-03-05 Ecole Polytechnique Federale De Lausanne (Epfl) Preparation and medical use of triazenes
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
KR20180018800A (ko) 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CA2989001A1 (en) 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936234B1 (https=) * 1968-09-09 1974-09-28

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936234B1 (https=) * 1968-09-09 1974-09-28

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6014005693; Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ，　Ｐｅｒｋｉｎ　Ｔｒａｎｓａｃｔｉｏｎｓ　２；　Ｐｈｙｓｉｃａｌ　Ｏｒｇａｎｉｃ　Ｃｈｅｍｉｓｔｒｙ Ｎｏ．１１, 1998, ｐ．２３６１-２３６３ *
JPN6014005695; Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３５，　Ｎｏ．１８, 1992, ｐ．３３７７-３３８２ *
JPN6014005697; Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２１，　Ｎｏ．６, 1978, ｐ．５６３-５７４ *
JPN6014005699; Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｓｃｉｅｎｃｅ Ｖｏｌ．６０，　Ｎｏ．４, 1971, ｐ．５５４-５６０ *
JPN6014005700; Ａｎｔｉｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．１９，　Ｎｏ．３Ａ, 1999, ｐ．２１２７-２１３１ *

Also Published As

Publication number Publication date
WO2010029577A2 (en) 2010-03-18
US8258119B2 (en) 2012-09-04
WO2010029577A3 (en) 2010-05-06
EP2324006A2 (en) 2011-05-25
KR20110063537A (ko) 2011-06-10
EP2324006B1 (en) 2014-08-13
CN102149703B (zh) 2014-09-10
CA2736732A1 (en) 2010-03-18
AU2009290365B2 (en) 2014-08-14
AU2009290365A1 (en) 2010-03-18
NZ591394A (en) 2013-03-28
CN102149703A (zh) 2011-08-10
IL211366A0 (en) 2011-04-28
BRPI0913485A2 (pt) 2016-06-07
US20100068178A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
EP2324006B1 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
JP5571168B2 (ja) 抗癌剤ならびに悪性黒色腫および他の癌に関連する使用
JP6219882B2 (ja) ＩＲＥ−１αインヒビター
US10315990B2 (en) Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof
JP2021503013A (ja) Ａｃｓｓ２阻害剤およびその使用方法
EA022690B1 (ru) Имидазопиридиновые производные, способ их получения и терапевтическое использование
JP2005506334A (ja) ＮＦ−κＢ阻害剤
JP2004523476A (ja) ＮＦ−κＢ阻害剤
JP2021504457A (ja) チエノ環系化合物およびその合成方法と応用
CN114080389A (zh) Nrf2活性化化合物
WO2003029241A1 (en) Chk1 kinase inhibitors
ES2782357T3 (es) Inhibidores de IRE 1 alfa
JP2004532797A (ja) ＮＦ−κＢ阻害剤
ES2285125T3 (es) Inhibidores de nf-kb.
CN106535894A (zh) 用于癌症治疗的mcl‑1调节化合物
US9278958B2 (en) Anti-cancer compounds
CN102600164B (zh) 嘧啶醚类化合物作为制备抗肿瘤药物的应用
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
KR101576235B1 (ko) 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물
CN121591767A (zh) 一种含有碳硼烷的化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140708